SUIT-019: Difference between revisions
From Bioblast
(Created page with "{{MitoPedia |abbr=FNSCIV_1PalM 2D 3c 4Oct 5P 6G 7U 8S 9Rot 10Ama 11Tm 12Azd |description=right|300px ''...") Β |
Beno Marija (talk | contribs) No edit summary Β |
||
(62 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{MitoPedia | {{MitoPedia | ||
|abbr= | |abbr=Pal+Oct+P+G_OXPHOS+S+Rot_ET | ||
|description=[[File: | |description=[[File:1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-.png|450px]] | ||
''' | |info='''A: | ||
}} | }} | ||
::: '''[[SUIT protocol pattern]]:''' 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot- | |||
SUIT-019 gives information on [[Fatty_acid_oxidation_pathway_control_state|F-pathway]] in [[LEAK respiration#The_LEAK_state |LEAK]] and [[Oxidative phosphorylation|OXPHOS]] states ([[P-L control efficiency |''P-L'' control efficiency]]). [[FN]]-pathway control is studied in the [[Oxidative phosphorylation|OXPHOS state]], and [[FN]]β[[FNS]]β[[S]] in the [[ET capacity| ET state]]. | |||
__TOC__ | |||
Communicated by [[Cardoso LHD]], [[Doerrier C]], [[Komlodi T]], [[Gnaiger E]] (last update 2020-11-13) | |||
== Specific SUIT protocols == | |||
=== SUIT-001 O2 mt D001 and SUIT-001 O2 pfi D002 === | |||
[[File:1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot;9Ama.png|450px]] | |||
[[File:D045_O2_traces.png|400px]] | |||
*Β [[SUIT-019 O2 pfi D045]] for [[Permeabilized_muscle_fibers|permeabilized muscle fibers]] | |||
{{Template:SUIT-019}} | |||
== Strengths and limitations == | |||
:::* SUIT-019 allows the study of OXPHOS capacity in the fatty acid oxidation (F) and fatty acid oxidation&NADH pathway (FN) control states. | |||
:::+ The protocol provides information on [[Fatty acid oxidation pathway control state| F-pathway]] (in presence of palmitoylcarnitine, and palmitoylcarnitine&octanoylcarnitine) in [[LEAK respiration|LEAK]] and [[OXPHOS]] states. In human heart muscle, the addition of octanoylcarnitine to palmitoylcarnitine&malate increased [[OXPHOS]] by 26% ([[Lemieux 2011 Int J Biochem Cell Biol |Lemieux H et al 2011]]). | |||
:::+ SUIT-019 provides information of the linear coupling (''L''-''P'') in FN-pathway. | |||
:::+ Maximum [[ET capacity]] in FNS-pathway is obtained in SUIT-019. | |||
:::+ P/E for FN-pathway (5G/6U) can be calculated. | |||
:::+ Reasonable duration of the experiment. | |||
:::- Octanoylcarnitine and palmitoylcarnitine can have an uncoupling effect on OXPHOS state if their concentration is not optimized. | |||
:::- In the presence of anaplerotic pathways F-pathway is overestimated. | |||
:::- CIV activity is not measured, to save experimental time. | |||
== Compare SUIT protocols == | |||
::::* [[SUIT-002]] (RP2): SUIT protocol specially designed to give information on F-pathway in OXPHOS state avoiding FAO overestimation in the presence of anaplerotic pathways.Β Moreover, the pathway control in OXPHOS state ([[Fatty_acid_oxidation_pathway_control_state|F]], F(N), [[FN]], [[FNS]], [[FNSGp]] pathways) and in [[ET capacity| ET state]] ([[FNSGp]] and [[SGp-pathway control state|SGp]]) can be evaluated by using this SUIT protocol. | |||
== References == | |||
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-019]] | |||
|?Was published in year=Year | |||
|?Has title=Reference | |||
|?Mammal and model=Organism | |||
|?Tissue and cell=Tissue;cell | |||
|format=broadtable | |||
|limit=5000 | |||
|offset=0 | |||
|sort=Was published in year | |||
|order=descending | |||
}} | |||
{{MitoPedia concepts | {{MitoPedia concepts | ||
|mitopedia concept=SUIT protocol | |mitopedia concept=MiP concept, SUIT protocol, Recommended | ||
}} | |||
{{MitoPedia methods | |||
|mitopedia method=Respirometry | |||
}} | }} | ||
Latest revision as of 12:33, 25 November 2020
Description
Abbreviation: Pal+Oct+P+G_OXPHOS+S+Rot_ET
Reference: A:
- SUIT protocol pattern: 1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-
SUIT-019 gives information on F-pathway in LEAK and OXPHOS states (P-L control efficiency). FN-pathway control is studied in the OXPHOS state, and FNβFNSβS in the ET state.
Communicated by Cardoso LHD, Doerrier C, Komlodi T, Gnaiger E (last update 2020-11-13)
Specific SUIT protocols
SUIT-001 O2 mt D001 and SUIT-001 O2 pfi D002
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1PalM | PalML(n) | F(N) | CETF | 1PalM
|
2D | PalMP | F(N) | CETF | 1PalM;2D
|
2c | PalMP | F(N) | CETF | 1PalM;2D;2c
|
3Oct | PalOctMP | F(N) | CETF | 1PalM;2D;2c;3Oct
|
4P | PalOctPMP | FN | CETF&CI | 1PalM;2D;2c;3Oct;4P
|
5G | PalOctPGMP | FN | CETF&CI | 1PalM;2D;2c;3Oct;4P;5G
|
6U | PalOctPGME | FN | CETF&CI&II | 1PalM;2D;2c;3Oct;4P;5G;6U
|
7S | PalOctPGMSE | FNS | CI&CII | 1PalM;2D;2c;3Oct;4P;5G;6U;7S
|
8Rot | SE | S | CII | 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot
|
9Ama | ROX | 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot;9Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- Β» Electron transfer pathway
- Β» Fatty acid oxidation pathway control state, F
- Β» NADH electron transfer-pathway state, N
- Β» Succinate pathway control state, S
- Β» NS-pathway control state, NS
- Β» Glycerophosphate pathway control state, Gp
- Β» Complex IV single step, CIV
- Β» Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- Β» Glutamate, G
- Β» Glycerophosphate, Gp
- Β» Malate, M
- Β» Octanoylcarnitine, Oct
- Β» Pyruvate, P
- Β» Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- SUIT-019 allows the study of OXPHOS capacity in the fatty acid oxidation (F) and fatty acid oxidation&NADH pathway (FN) control states.
- + The protocol provides information on F-pathway (in presence of palmitoylcarnitine, and palmitoylcarnitine&octanoylcarnitine) in LEAK and OXPHOS states. In human heart muscle, the addition of octanoylcarnitine to palmitoylcarnitine&malate increased OXPHOS by 26% (Lemieux H et al 2011).
- + SUIT-019 provides information of the linear coupling (L-P) in FN-pathway.
- + Maximum ET capacity in FNS-pathway is obtained in SUIT-019.
- + P/E for FN-pathway (5G/6U) can be calculated.
- + Reasonable duration of the experiment.
- - Octanoylcarnitine and palmitoylcarnitine can have an uncoupling effect on OXPHOS state if their concentration is not optimized.
- - In the presence of anaplerotic pathways F-pathway is overestimated.
- - CIV activity is not measured, to save experimental time.
Compare SUIT protocols
- SUIT-002 (RP2): SUIT protocol specially designed to give information on F-pathway in OXPHOS state avoiding FAO overestimation in the presence of anaplerotic pathways. Moreover, the pathway control in OXPHOS state (F, F(N), FN, FNS, FNSGp pathways) and in ET state (FNSGp and SGp) can be evaluated by using this SUIT protocol.
References
Year | Reference | Organism | Tissue;cell | |
---|---|---|---|---|
Lemieux 2011 Int J Biochem Cell Biol | 2011 | Lemieux H, Semsroth S, Antretter H, HΓΆfer D, Gnaiger E (2011) Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int J Biochem Cell Biol 43:1729β38. https://doi.org/10.1016/j.biocel.2011.08.008 | Human | Heart |
MitoPedia concepts:
MiP concept,
SUIT protocol,
Recommended
MitoPedia methods:
Respirometry